Meeting EU Drinking Water Standards: The Critical Role of Sample Prep in Trace Contaminant Analysis

Although modern agriculture needs to be based on accurate real-time data on soil, plant, and environmental conditions, affordable, sufficiently sensitive, and robust monitoring devices for this purpose are currently missing. According to scientists, low-cost sensors based on new smart materials and printing technologies offer a suitable solution. The results of multidisciplinary research thus far and proposals for the development of these devices have been presented by researchers from Czechia, Great Britain, Spain, and the USA in a review article in the prestigious journal <a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41467-026-68778-6#Abs1">Nature Communications</a>.“Sensor technologies for monitoring plant health are still in their infancy. Only simple sensors capable of monitoring basic parameters such as pH, soil moisture, or temperature are commonly available on the market. However, if farmers are to face current challenges, including climate change, and ensure sufficient food for humanity, they need much more effective tools that will enable them to monitor, for example, various pathogens, including bacteria and fungi. In our opinion, a suitable solution is a combination of new smart materials and printing for the production of inexpensive, durable, and scalable materials,” said the article’s first author, David Panáček from CATRIN, who worked on the study during his internship at Imperial College London.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/CATRIN_Soucasne_senzory_nestaci_Vedci_navrhuji_novou_cestu_ke_sledovani_zdravi_rostlin_b4014952a3.jpg" alt="CATRIN: David Panáček" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_CATRIN_Soucasne_senzory_nestaci_Vedci_navrhuji_novou_cestu_ke_sledovani_zdravi_rostlin_b4014952a3.jpg 208w," sizes="100vw" width="1536" height="1152">Sensors for monitoring plant health, for example, lag behind similar devices used in human medicine. According to the authors, advances in materials science, which will enable the development of scalable sensor technologies, play a key role in this potential shift. “Printing techniques, including inkjet printing, screen printing, aerosol printing, 3D printing, and direct laser writing, offer flexible ways to produce flexible sensors, large-area sensors, and sensors integrated directly into plants. The review article summarizes recent advances in printable low-dimensional materials for agricultural sensors, analyzes their physico-chemical properties in relation to sensor performance, and discusses key challenges and future opportunities requiring interdisciplinary integration,” said one of the corresponding authors, Michal Otyepka.The research brought together materials scientists, chemists, biologists, sensing experts, and printing technology specialists. Materials research and the use of graphene-based smart materials were led by scientists from CATRIN at Palacký University and VŠB-Technical University of Ostrava. Plant biologists from CATRIN contributed their knowledge of plant development, their responses to stress conditions, and the monitoring of their properties. Researchers from Imperial College London took care of the electronics, while representatives from<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/companies/36"> CEITEC – VUT</a> focused on printing technologies. The team also included leading experts in sensing from the Catalan Institute of Nanoscience and Nanotechnology in Barcelona, and Joseph Wang of the University of California San Diego, the “father of sensing and electrochemistry,” also contributed his extensive knowledge.“This is a groundbreaking study on this topic, which has managed to attract some truly big names in their respective fields. Last but not least, the study demonstrates that interdisciplinarity at CATRIN gives rise to completely new and promising research topics, such as plant sensing and its use for studying plant-environment interactions and smart agriculture,” added another corresponding author, Nuria De Diego.

Current sensors are not good enough. Scientists propose a new way to monitor plant health

In this episode of the Concentrating on Chromatography podcast, host David Oliva interviews Ainslie Chen about her cutting-edge research on hemoglobin variant testing using liquid chromatography-high resolution mass spectrometry (LC-HR-MS). Ainslie discusses her novel method for separating and identifying hemoglobin subunits with mass shifts less than 1 Da, overcoming critical limitations in conventional clinical assays.Hear firsthand how her team developed an LC-HR-MS workflow using a C4 reversed-phase column, tackled technical challenges (including why C18 columns fell short), and achieved unprecedented sensitivity for variant detection in both adult and neonatal samples. The conversation touches on the potential of mass spectrometry to revolutionize clinical diagnostics, the importance of reproducibility, barriers to adoption in routine labs, and how teamwork drives scientific innovation.Perfect for analytical chemists, clinical laboratorians, and anyone interested in the future of protein variant analysis, this episode also features Ainslie’s advice for early-career scientists and insights from her first ACS poster presentation.<h4>Key Highlights:</h4><ul><li>Motivation behind improving hemoglobinopathy testing &nbsp;</li><li>Technical advantages of LC-HR-MS over gene sequencing and CE &nbsp;</li><li>The crucial role of the C4 column in resolving challenging samples &nbsp;</li><li>Critical parameters for reproducible LC-HR-MS workflows &nbsp;</li><li>Barriers and outlook for clinical adoption of advanced mass spectrometry &nbsp;</li><li>The value of teamwork and mentorship in scientific research &nbsp;</li><li>Direct insights from recent ACS conference experiences</li></ul><h3>Video transcription</h3>In this interview, Ainslie Chen discusses her research on improving the detection and identification of hemoglobin variants using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). The work addresses limitations of conventional hemoglobinopathy testing, which often struggles to resolve very small mass differences between closely related hemoglobin subunits. Because even a single amino-acid substitution can significantly alter hemoglobin structure and function, high analytical resolution is essential for accurate diagnosis of conditions such as anemia and sickle cell disease.Chen explains why her team selected LC-HRMS over established clinical techniques like capillary electrophoresis and gene sequencing. While sequencing offers excellent accuracy, it is time-consuming, costly, and requires extensive sample preparation, making it impractical for routine clinical workflows. Capillary electrophoresis enables subunit separation but lacks the resolving power needed to distinguish variants differing by less than one Dalton. In contrast, high-resolution mass spectrometry provides both structural specificity and sensitivity, enabling confident identification of subtle hemoglobin variants with minimal sample preparation.A key methodological insight from the project was the use of a C4 reversed-phase LC column instead of the more common C18 column. Chen describes how the shorter carbon chain and larger pore size of C4 columns improved protein elution and reduced denaturation, leading to more reproducible separations. Critical parameters for reproducibility included consistent mobile-phase composition (0.1% formic acid in water and acetonitrile), controlled temperature (60 °C for LC, ~320 °C capillary temperature), and stable chromatographic conditions.Beyond hemoglobin analysis, Chen highlights the broader potential of high-resolution mass spectrometry in proteoform analysis and clinical diagnostics, including emerging applications in cancer detection. She acknowledges current barriers to clinical adoption—such as energy demands and instrument infrastructure—but points to advances like miniaturized mass spectrometers as promising steps toward wider use. The interview concludes with advice for young scientists: don’t hesitate to reach out to mentors, embrace collaboration, and view analytical chemistry as a versatile tool that bridges medicine, biology, environmental science, and beyond.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Unlocking Hemoglobin Variant Detection: LC-HR-MS Breakthrough with Ainslie Chen

Article

Video

Environment

Scientific article

Interview

Science and research

The Czech Advanced Technology and Research Institute (CATRIN) at Palacký University is a cutting-edge scientific hub dedicated to advancing research in the fields of nanotechnology, biotechnology, and biomedicine. At its core, CATRIN boasts outstanding scientific teams, featuring international researchers. We emphasize interdisciplinarity, foster global collaborations, and work to translate our research findings into practical applications.

CATRIN

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Agilent Technologies

Technology Networks

Thermo Fisher Scientific

Wiley

Shimadzu Corporation

Waters Corporation

Join us for the fourth SELECT SERIES MRT in Action deminar. In this installment of our series, we will show new levels of imaging clarity and confidence being obtained with MRT, at speeds that realize useful improvements in throughput.
In our applications demo lab we will show the simplicity of changing between MALDI and DESI XS modes, both available on the MRT instrument. We will also highlight new imaging workflows, enabled by micro apps, developed to extract meaningful information quickly.
The session will conclude with a live Q&amp;A where Emmanuelle Claude, Wei Rao and other members of the team, who will be on hand to answer all of your questions. 
Why Should You Attend?
<ul>
<li>Discover how the characteristics of the MRT aid mass spectrometry imaging workflows</li>
<li>Learn how the different imaging modes work to extend imaging coverage</li>
<li>Understand how MRT imaging data is processed through various workflows</li>
</ul>
<blockquote>
Presenter: Emmanuelle Claude (Consulting Scientist, Waters Corporation)
</blockquote>
<blockquote>
Emmanuelle Claude started at Waters Corporation in October 2000 as an Applications Chemist in the Proteomics and Genomics Marketing group, developing automated Peptide Mass Fingerprint (PMF) MS methods using a MALDI-TOF mass spectrometer. Over the years she developed several methods in the proteomics analytical space using MALDI TOF and naturally moved in starting the development of Mass Spectrometry Imaging (MSI) at Waters corporation over 15 years ago.
</blockquote>
<blockquote>
She has been involved with hardware and software R&amp;D to ensure that the solutions are fit-for-purpose for the MSI community and beyond. She has worked extensively with the main MSI leaders in Europe and the US such as Prof Heeren in the Netherlands, Prof Clench, Prof Takats and Bunch in the UK and Prof Caprioli in the US. She has been a Principal Scientist since 2014 and became a Consulting scientist in 2021. Emmanuelle is managing the MS imaging application team at Waters, who are involved in developing new applications and methods for imaging by both MALDI and DESI mass spectrometry.
</blockquote>
<blockquote>
Presenter: Wei Rao (Principal Applications Chemist, Waters Corporation)
</blockquote>
<blockquote>
Wei Rao is currently working as a Principal Applications Chemist in the European Applications Laboratory at Waters Wilmslow, focusing on MS imaging and ambient MS with the DESI XS platform. He has more than 12 years of ambient MS imaging experience, and has worked in various posts in the UK, US, China, and many countries within the APAC region, bringing with him a unique global perspective to the field.
</blockquote>

Accelerated Imaging Clarity

In our applications demo lab we will show the simplicity of changing between MALDI and DESI XS modes, both available on the MRT instrument.

In this virtual Ask Me Anything session we are offering you a chance to delve into the fascinating world of PFAS (Per- and Polyfluoroalkyl Substances).
We are honored to present Dr. Carol Kwiatkowski, a distinguished science and policy senior associate from Green Science Policy, as our esteemed guest.
Dr. Kwiatkowski will be your guide, providing expert insights and answering all your questions about PFAS. From its profound health and environmental concerns to the ever-evolving landscape of regulations, restrictions, and detection techniques. No question is off limits! 
During this session, you can expect to:
<ul>
<li>Engage in a Live Q&amp;A: Seize the opportunity to directly interact with Dr. Kwiatkowski, posing your most thought-provoking questions, and receive real-time, well-informed answers.
</li>
<li>Gain Expert Perspectives: Immerse yourself in a vibrant exchange of ideas, as Dr. Kwiatkowski shares her profound insights on questions posed by fellow participants.
</li>
</ul>
<blockquote>
Presenter: Dr. Carol Kwiatkowski (Adjunct Assistant Professor, North Carolina State University)
</blockquote>

Technology Networks: Ask Me Anything: PFAS

Ask Me Anything: PFAS

Delve into the fascinating world of PFAS.

Join us for a live presentation highlighting the uses of the Xevo G3 QTof mass spectrometer in a case study of biosimilar mAb characterization at intact, subunit, and peptide level.
<blockquote>
Presenter: Samantha Ippoliti (Principle Scientist, Discovery &amp; Development- Biopharma, Waters Corporation)
</blockquote>
<blockquote>
Sam joined Waters (Milford, MA) in 2018 and has worked on a variety of applications for LC-MS based biopharmaceutical characterization, including peptide mapping analysis and method development, and intact/subunit analysis via reversed phase (RP) and ion exchange (IEX) -MS. Prior to joining Waters, she was part of the LC-MS characterization group supporting a biopharmaceutical developability assessment group at Novartis in Cambridge, MA. Sam acquired a BS-MS in Chemistry from Northeastern University in 2012.
</blockquote>

Waters Corporation: Robust Multi-Level LC-MS Workflows for Biosimilar Comparability Assessment

Robust Multi-Level LC-MS Workflows for Biosimilar Comparability Assessment

Uses of the Xevo G3 QTof mass spectrometer in a case study of biosimilar mAb characterization at intact, subunit, and peptide level.

Robust Multi-Level LC-MS Workflows  for Biosimilars

Learn how to improve assay robustness and reduce the burden associated with migrating methods downstream in the analysis and monitoring of product quality attributes of biopharmaceuticals.
<blockquote>
Presenter: Pawel Bigos (Scientist, Waters Corporation)
</blockquote>
<blockquote>
Pawel is a Scientist at Waters Corporation in the QA/QC Biologics group. He joined Waters in 2022 and has primarily focused on biomolecule separations using Ion-Exchange (IEX) and Size Exclusion (SEC) Chromatography. Prior to Waters, he held positions at Frequency Therapeutics, Novartis, and Symbiotic Research. Pawel received his BS degree in chemistry from the University of South Florida.
</blockquote>

Waters Corporation: Advancing Technology for Better Medicine

Advancing Technology for Better Medicine

Learn how to improve assay robustness and reduce the burden associated with migrating methods downstream.

Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.
In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing. This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.
<blockquote>
Presenter: Carrie McDonough, PhD (Carnegie Mellon University)
</blockquote>

Agilent Technologies: Towards more Comprehensive Characterization of PFAS Exposure using Ion Mobility and High-Resolution Mass Spectrometry

Towards more Comprehensive Characterization of PFAS Exposure using Ion Mobility and High-Resolution Mass Spectrometry

Towards more Comprehensive Characterization of PFAS Exposure using Ion Mobility and High-Resolution Mass Spectrometry.

Characterization of PFAS Exposure using IM and HRMS

Emerging therapies like Synthetic Peptides &amp; Oligonucleotides are catching the attention due to its capabilities to improve their physicochemical and biological properties, such as efficacy, stability, bioavailability, safety, etc.
These require thorough understanding &amp; analysis of these molecules and exclusive strategies to quantify these molecules in various biological matrices.
<blockquote>
Presenter: Dr. Ravi Shah (M.S.; PhD), (Head of the Department - Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research - Ahmedabad)
</blockquote>
<blockquote>
Dr. Ravi is Head of the Department of pharmaceutical analysis at NIPER- Ahmedabad. He has received his M.S. (Pharm) and PhD from NIPER, Mohali under the guidance of Prof. Saranjit Singh. Before joining back to academic research, he served at various levels in industry to understand the needs of pharma sector. He had started his career with Biocon-BMS research and development center, where he was responsible for analytical activities related to IND and NDA fillings of drug discovery leads. Post drug discovery understanding, he joined Dr. Reddy’s in 2015 as associate director and department head for Analytical R&amp;D Bangalore facility to learn generic drug development. He gathered vast experience on analytical method development, and regulatory requirements pertaining to DMF/ ANDA fillings at US and EU. He also worked significantly on complex generics for getting pharmaceutical equivalence through robust CQA, CPP and CMA correlations through QbD approaches.
</blockquote>
<blockquote>
He has published many research articles in almost every international analytical journal like Analytical Chemistry, Drug Testing and Analysis, Journal of Chromatogaphy A,Journal of Chromatogaphy B,Journal of Pharmaceutical and Biomedical Analysis, Trends in Analytical Chemistry, Analytical Methods, Analytical and Bioanalytical Chemistry, Rapid communications in mass spectrometry etc.
</blockquote>
<blockquote>
Presenter: Dr. Ashish Pargaonkar (Biopharma Workflow Commercialization Lead, Agilent Technologies)
</blockquote>
<blockquote>
Dr. Ashish Pargaonkar is a Lead for Biopharma Workflow Commercialization team for India and also Manager for Centre of Excellences at Bangalore. A Microbiologist by education with a Ph.D, he holds more than 20 years of experience for Biopharma market applications on Hi Resolution Mass Spectrometry. He has a long record of successful demonstrations and customer engagements on workflows for CQA’s, Intact mass, peptide mapping, HCP and Glycans using Agilent state-of-the art solutions. He has authored ASMS posters on media components and therapeutic peptides. Dr. Ashish has been invited speaker at several conferences and workshops at Biosimilar Congress, ADC 2018, IIT (Mumbai, Delhi), ICT (Mumbai), PSI events.
</blockquote>
<blockquote>
Presenter: Ms. Paramjeet Khandpur (Biopharma Workflow Commercialization Lead, Agilent Techologies)
</blockquote>
<blockquote>
Paramjeet Khandpur, M.Tech., holds a bachelor’s degree in chemical engineering from VTU University and a Master&#39;s in Bioprocess Technology from the Institute of Chemical Technology, Mumbai. Paramjeet is currently the Biopharma Workflow Commercialization Lead at Agilent. In this role, she leverages her expertise to deliver comprehensive workflow solutions and offer support to customers, catering to their analytical requirements across the Biopharma value chain.
</blockquote>
<blockquote>
Previously, she worked as an Application Engineer at Agilent&#39;s Centre of Excellence Lab in Bangalore, specializing in various liquid chromatography platforms. She also collaborated with users in the Pharma and Biopharma industry for method development, troubleshooting, and method transfer.
</blockquote>

Agilent Technologies: Get the Perfect Answer for Synthetic Peptides & Oligonucleotides

Get the Perfect Answer for Synthetic Peptides & Oligonucleotides

Emerging therapies like Synthetic Peptides & Oligonucleotides are catching the attention due to its capabilities to improve their properties.

Get the Perfect Answer for Synthetic Peptides

This online event is aimed at those working within academia and pharmaceutical drug development, who want to hear from experts across their field. Focus will be given to the latest advances in small molecule drug discovery and development, biopharma and biotechnology.
This online symposium will cover:
<ul>
<li>Accelerating drug discovery through AI
</li>
<li>Molecular dynamics simulations for novel drug targets
</li>
<li>Allosteric small-molecule activation of PI 3-kinase for cardioprotection and neuroregeneration
</li>
<li>Analytical solutions for challenging nitrosamine quantitation using LC-MS
</li>
<li>Screening in organoids and complex 3D assays using high-content imaging
</li>
<li>Paucity of novel oncology targets
</li>
<li>An interactive Ask-Me-Anything session where you can pose your questions to thought leadership experts at the forefront of biopharmaceutical commerce
</li>
</ul>
<h3>Agenda Day 2</h3>
<h5>16:00 – 16:30 Screening in Organoids &amp; Complex 3D Assays Using High Content Imaging</h5>
<ul>
<li>Speaker: Michiel Fokkelman, PhD</li>
</ul>
<h5>16:30 – 16:40 Networking Break</h5>
<h5>16:40 – 17:00 Enhancing Safety and Quality Assurance in Cell Based Therapies and ATMPS: The Power of Rapid NAT-Based Mycoplasma Detection</h5>
<ul>
<li>Speaker: Michael Brewer</li>
</ul>
<h5>17:00 – 17:10 Networking Break</h5>
<h5>17:10 – 18:00 Call to Action: Critical Need to Address the Paucity of Novel Oncology Targets</h5>
<ul>
<li>Speaker: Brian D. Lamon, PhD</li>
</ul>
<h5>18:00 – 18:10 Networking Break</h5>
<h5>18:10 – 18:30 Target Discovery and Validation with Arrayed Cell Libraries</h5>
<ul>
<li>Speaker: Alexander Brown, PhD</li>
</ul>
<h5>18:30 – 18:40 Networking Break</h5>
<h5>18:40 – 19:30 To Improve the Selectivity and Sensitivity of Chimeric T-Cell Receptor for Treating Solid Tumours</h5>
<ul>
<li>Speaker: Chun Wu, PhD</li>
</ul>
<blockquote>
Presenter: Joshua Smith, PhD (Global Lead for Industry Partnerships, IBM Research)
</blockquote>
<blockquote>
Presenter: Dr. Chun Wu (Associate Professor, Departments of Chemistry &amp; Biochemistry and the Biological Biomedical Sciences – Rowan University)
</blockquote>
<blockquote>
Presenter: Dr. Bart Vanhaesebroeck (Professor, Cancer Institute, University College London)
</blockquote>
<blockquote>
Presenter: Dr. Grace Gong (Research Fellow, Cancer Institute, University College London)
</blockquote>
<blockquote>
Presenter: David Pardoe (SVP Global Molecular Architects, Evotec)
</blockquote>
<blockquote>
Presenter: Carla Marchioro (VP Scientific Director Global Molecular Architects, Evotec)
</blockquote>
<blockquote>
Presenter: Jack Steed (Senior Technical Marketing Specialist, Sciex)
</blockquote>
<blockquote>
Presenter: Michael Brewer (Director, Global Principal Consultant, Regulatory, BioProduction, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Presenter: Michiel Fokkelman, PhD (Head of High Throughput Screening, Crown Bioscience Netherlands)
</blockquote>
<blockquote>
Presenter: Brian Lamon, PhD (Senior Vice President, Chief Business Officer and Head of BioPharma Business Development, Caris Life Sciences)
</blockquote>
<blockquote>
Presenter: Alexander Brown, PhD (Associate Director ECLIPSE Development, Synthego)
</blockquote>
<blockquote>
Presenter: Mike Ward (Global Head of Life Sciences &amp; Healthcare Thought Leadership, Clarivate plc)
</blockquote>

LabRulez/AI: Advances in Drug Discovery & Development 2023

Advances in Drug Discovery & Development 2023 (Day 2)

The latest advances in small molecule drug discovery and development, biopharma and biotechnology.

Advances in Drug Discovery & Development 2023 (Day 1)

Comparing MS spectra to libraries of reference spectra is one of the most widely used and successful methodologies in the identification of unknown mass spectra. Using this approach, access to an expansive, quality dataset is critical to achieving reliable results.
In this session we will introduce the latest release of the Wiley Registry® / NIST Mass Spectral Library 2023, which combines the power of two trusted MS spectral libraries to provide comprehensive compound coverage and ensure identification across multiple use cases and a wide variety of analytes.
In this session, we will also demonstrate through a series of live examples how this library can be used to successfully identify unknown spectra.
<blockquote>
Presenter: Dr. Nadia Laschuk
</blockquote>
<blockquote>
Dr. Nadia Laschuk is a Product Manager for Wiley Science Solutions, for which she manages new products and databases while supporting existing KnowItAll capabilities. Nadia previously completed her PhD in Materials Science from Ontario Tech University, where she performed research applying a wide array of instrumental techniques to analyze metal-organic coordination compounds. Nadia has since pursued cheminformatics and software, joining Wiley in 2022.
</blockquote>

Wiley: Increase the Likelihood of MS Identification with the Wiley Registry / NIST Library

Increase the Likelihood of MS Identification with the Wiley Registry / NIST Library

The latest release of the Wiley Registry® / NIST Mass Spectral Library 2023, which combines the power of two trusted MS spectral libraries.

MS Identification with the Wiley Registry / NIST Library

Introducing Shimadzu’s Multimodal Imaging System, designed to provide advanced clinical imaging and accelerate research breakthroughs. The powerful system consists of two instruments: the Laser-ablation ICP-MS, which acquires information on the element distribution, and the award-winning iMScope QT MALDI-MS Microscope, which provide information on the compound distribution. The data from both instruments can be seamlessly analyzed using the intuitive IMAGEREVEAL MS software without the need for special data conversion. This integrated data analysis unlocks unparalleled insights into the spatial distribution of elements and biomolecules within tissues and cells, thereby opening up new avenues for diagnostics, biomarker discovery, and drug development.
Join us at our Shimadzu Digital Classrooms as we delve into the world of Multimodal Imaging by exploring real-world application case studies. Experience firsthand how this cutting-edge technology, together with integrated data analysis, provides profound insights quickly and accurately to advance clinical research.
Don&#39;t miss this opportunity to discover the capabilities of Shimadzu&#39;s multimodal imaging system - Register now!
<h3>Learning Objectives:</h3>
<ul>
<li>Discover capabilities of Shimadzu&#39;s Multimodal Imaging System, integrating LA-ICPMS and MALDI-MS Microscopy</li>
<li>Gain comprehensive insights into Shimadzu&#39;s complete solution for LA-ICP-MS</li>
<li>Learn about Shimadzu iMScope QT, a Next-Generation Mass Spectrometry Imaging system</li>
<li>Explore real-world clinical application case studies leveraging the Multimodal Imaging approach</li>
</ul>
<blockquote>
Presenter: Pravin Konde, PhD (Senior Product Specialist, Shimadzu (Asia Pacific) Pte Ltd)
</blockquote>
<blockquote>
Pravin Konde is a Senior Product Specialist (for Spectroscopy &amp; TOC) at Shimadzu Asia Pacific Singapore. He has about 15 years of industry experience of which about 12 years in analytical instruments with expertise in trace element analysis and spectroscopy applications. He is engaged primarily in technical support to regional sales teams and customers. Prior to joining industry, he has done his PhD in Chemistry from Institute of Chemical Technology (formerly UDCT), Mumbai, India.
</blockquote>
<blockquote>
Presenter: Naatasha Isahak, PhD (Product Specialist (Life Sciences), Shimadzu (Asia Pacific) Pte Ltd)
</blockquote>
<blockquote>
Naatasha Isahak is a Product Specialist for MALDI and Life Sciences Products from Shimadzu Asia Pacific Pte Ltd. She has received her PhD from the University of Sydney (Chemistry) working on surface initiated polymerisation on silica nanoparticles using RAFT polymerisation and bioorthogonal conjugation of peptides using Native Chemical Ligation. She then spent 5 years working on developing platforms for stem cells and organoids characterization that included working with microfluidic devices and helical polymers. Naatasha joined Shimadzu in 2022 to expand her experiences to MALDI characterization on materials and biological samples.
</blockquote>

Shimadzu: Powerful Multimodal Clinical Imaging System with LA-ICP-MS and MALDI-MS Microscopy

Powerful Multimodal Clinical Imaging System with LA-ICP-MS and MALDI-MS Microscopy

LA-ICP-MS, which acquires information on the element distribution & iMScope QT MALDI-MS Microscope, which provide information on the compound distribution.

Clinical Imaging with LA-ICP-MS and MALDI-MS Microscopy

The successful development of effective mRNA-based vaccines to fight Covid-19 has created a boost in acceptance and application of this strategy for other vaccines and also related drug products. Consequently, the demand to analytically characterize these new modalities has risen, challenging the state-of-the-art analytical approaches to keep pace.
In this webinar we showcase how novel techniques together with modern instrumentation and data analysis software can further the understanding of this new drug class, thereby ensuring the efficacy and safety of the drug product.
The identity and sequence validation of the mRNA after limited endonuclease digestion and mass spectrometric sequence confirmation is demonstrated. Tips and tricks for successful method development and data handling in Biopharma finder software will be presented, including the use of the software to address 5’-Capping and poly(A) tail characterization.
We hope to see you there! 
<h3>Learning points:</h3>
<ul>
<li>How novel techniques together with modern instrumentation and data analysis software can further the understanding of this new drug class, thereby ensuring the efficacy and safety of the drug product.</li>
<li>Demonstration of identity and sequence validation of the mRNA after limited endonuclease digestion and mass spectrometric sequence confirmation</li>
<li>Tips and tricks for successful method development and data handling in Biopharma finder software</li>
</ul>
Who should attend:
<ul>
<li>Biopharmaceutical Research Scientists </li>
<li>Analytical Scientists from Biopharma companies working on or interested in oligonucleotide-based therapies. </li>
<li>PhD students in any field of biotherapeutic drug development </li>
<li>Scientists looking to advance knowledge of oligonucleotide analysis.</li>
</ul>
<blockquote>
Presenter: Dr. Alexander Schwahn (European Application Expert for BioPharma Industry, Thermo Fisher Scientific)
</blockquote>
<blockquote>
Presenter: Aude Croguennec (Moderator, Regional Marketing Manager, Thermo Fisher Scientific)
</blockquote>

Thermo Fisher Scientific: Characterization of mRNA-based therapeutics with (U)HPLC and HRAM mass spectrometry

Characterization of mRNA-based therapeutics with (U)HPLC and HRAM mass spectrometry

In this webinar we showcase how novel techniques together with modern instrumentation and data analysis software.

LCMS webinars focusing on LC/MS - page 74